Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity
- PMID: 29061729
- PMCID: PMC5741144
- DOI: 10.2337/db17-0802
Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity
Abstract
We examined the association between plasma 25-hydroxyvitamin D [25(OH)D] concentration and islet autoimmunity (IA) and whether vitamin D gene polymorphisms modify the effect of 25(OH)D on IA risk. We followed 8,676 children at increased genetic risk of type 1 diabetes at six sites in the U.S. and Europe. We defined IA as positivity for at least one autoantibody (GADA, IAA, or IA-2A) on two or more visits. We conducted a risk set sampled nested case-control study of 376 IA case subjects and up to 3 control subjects per case subject. 25(OH)D concentration was measured on all samples prior to, and including, the first IA positive visit. Nine polymorphisms in VDR, CYP24A, CYP27B1, GC, and RXRA were analyzed as effect modifiers of 25(OH)D. Adjusting for HLA-DR-DQ and ancestry, higher childhood 25(OH)D was associated with lower IA risk (odds ratio = 0.93 for a 5 nmol/L difference; 95% CI 0.89, 0.97). Moreover, this association was modified by VDR rs7975232 (interaction P = 0.0072), where increased childhood 25(OH)D was associated with a decreasing IA risk based upon number of minor alleles: 0 (1.00; 0.93, 1.07), 1 (0.92; 0.89, 0.96), and 2 (0.86; 0.80, 0.92). Vitamin D and VDR may have a combined role in IA development in children at increased genetic risk for type 1 diabetes.
© 2017 by the American Diabetes Association.
Figures
References
-
- Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep 2013;13:795–804 - PubMed
-
- Rosen Y, Daich J, Soliman I, Brathwaite E, Shoenfeld Y. Vitamin D and autoimmunity. Scand J Rheumatol 2016;45:439–447 - PubMed
-
- Kimlin MG. Geographic location and vitamin D synthesis. Mol Aspects Med 2008;29:453–461 - PubMed
-
- Hyppönen E, Läärä E, Reunanen A, Järvelin M-R, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500–1503 - PubMed
MeSH terms
Substances
Grants and funding
- U01 DK063821/DK/NIDDK NIH HHS/United States
- UC4 DK063863/DK/NIDDK NIH HHS/United States
- HHSN267200700014C/DK/NIDDK NIH HHS/United States
- U01 DK063861/DK/NIDDK NIH HHS/United States
- UL1 TR001427/TR/NCATS NIH HHS/United States
- U01 DK063790/DK/NIDDK NIH HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
- P30 DK017047/DK/NIDDK NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- U01 DK063836/DK/NIDDK NIH HHS/United States
- U01 DK063829/DK/NIDDK NIH HHS/United States
- U01 DK063865/DK/NIDDK NIH HHS/United States
- UC4 DK095300/DK/NIDDK NIH HHS/United States
- UC4 DK063861/DK/NIDDK NIH HHS/United States
- UC4 DK063829/DK/NIDDK NIH HHS/United States
- UC4 DK063821/DK/NIDDK NIH HHS/United States
- UC4 DK117483/DK/NIDDK NIH HHS/United States
- UC4 DK063836/DK/NIDDK NIH HHS/United States
- UC4 DK112243/DK/NIDDK NIH HHS/United States
- UC4 DK063865/DK/NIDDK NIH HHS/United States
- U01 DK063863/DK/NIDDK NIH HHS/United States
- UC4 DK106955/DK/NIDDK NIH HHS/United States
- UC4 DK100238/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
